« Back
Home /
Remetinostat

Remetinostat

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Item no.	HY-100365-50mg
Targets	HDAC
CASRN	946150-57-8
eClass 6.1	30220300
eClass 9.0	32160605
Available
Alias	SHP-141
Purity	98.0
Product Description	Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	323.34
Clinical_Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 150 mg/mL (ultrasonic)
Manufacturers Target	HDAC
Pathway	Cell Cycle/DNA Damage; Epigenetics

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100365-50mg-safety-datasheet.pdf